Effect of impaired kidney function on outcomes and treatment effects of oral anticoagulant regimes in patients with atrial fibrillation in a real-world registry
Findings from our large real-life registry confirm the data from RCTs and extend our knowledge on the effectiveness and safety of DOACs to subjects that were underrepresented in RCTs.
Authors
- Norbert Frey (ORCID: https://orcid.org/0000-0001-7611-378X)
- Christian Salbach (ORCID: https://orcid.org/0000-0002-1799-545X)
- Barbara Ruth Milles (ORCID: https://orcid.org/0009-0004-4602-5489)
- Mustafa Yı́ldı́rı́m (ORCID: https://orcid.org/0000-0001-6874-9294)
- Evangelos Giannitsis
- Matthias Mueller‐Hennessen
- Moritz Biener (ORCID: https://orcid.org/0000-0001-6763-6538)
- Hugo Katus
- Hauke Hund
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1371/journal.pone.0310838
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- AstraZeneca
- Bayer
- ZOLL Medical Corporation
- Daiichi-Sankyo
- Bayer Vital
- Daiichi Sankyo Europe